Sequencing the mouse genome is unlikely to provoke a fund-raising spate like that which flowed from the publication of its human counterpart, but Paradigm Therapeutics Ltd. was keen to stress its murine credentials this week when it announced the completion of a £12 million (US$19 million) second-round funding. (BioWorld International)